EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The European Medicines Agency authorised Rinvoq (upadacitinib) from AbbVie Deutschland GmbH & Co. KG for rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 17/11/2025